We are seeking people with a condition, Diabetic Kidney Disease (DKD), to participate in a study. The study is testing a new way of treating DKD with an drug called "propagermanium".
Propagermanium is an experimental treatment in Australia. This means it has not been approved by the Therapeutic Goods Administration for treatment of DKD in Australia however it has been licensed for use in Japan since 1994 for the treatment of chronic hepatitis B infection.
The purpose of this trial is to test if propagermanium is safe and effective in treating participants with DKD who are on a daily dose of 300 mg irbesartan when compared to placebo.
This study will determine how safe and effective the drug is by:
- monitoring symptoms that you may experience while on the study;
- measuring levels of albuminuria and your kidney function during the course of the study;
- measuring the levels of propagermanium and irbesartan that enters your blood and urine.
Primary biliary cholangitis (PBC) is a chronic disease in which the bile ducts in your liver are slowly destroyed. Human studies have shown that seladelpar may be useful for treating the signs and symptoms of PBC and lower alkaline phosphatase (AP) level and decrease itching.
The purpose of this research is to evaluate the safety and effectiveness of an investigational drug, seladelpar, in treating patients with PBC.
The purpose of this study is to find out if Cabozantinib in combination with Atezolizumab is effective in treating liver cancer (hepatocellular carcinoma) compared to Sorafenib alone in people who have not received prior treatment.
This study will also examine how well people with liver cancer who have not received prior treatment tolerate Cabozantinib alone, and how well it works in treating their cancer.
The immune system is the body’s natural defense against disease. The immune system sends types of cells called T cells throughout the body to detect and fight infections and diseases, including cancers. One way the immune system controls the activity of T cells is through a process called the PD-1 pathway. Some cancer cells hide from T-cell attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Immunotherapy drugs work by blocking the PD-1 pathway helping the immune system detect and fight cancer cells.
CBT-501, one of the experimental treatments in this research project, also blocks the PD-1 pathway.
This study involves research about CBT-101, a substance that blocks a type of enzyme called a kinase. Human cells have many different kinases, and they help control important functions, such as cell signaling, metabolism, division, and survival.
The combination of CBT-501 with CBT-101 is a new immunotherapy approach to see if CBT-101 possibly enhances the effectiveness of CBT-501 in liver tumours. CBT-501 and CBT-101 have demonstrated anti-tumour effects in animal studies. They are currently being studied in humans in other research studies.
he purpose of the study is to evaluate the safety and effectiveness of the study drug tezepelumab alone, or in combination with a topical corticosteroid, in the treatment of moderate to severe atopic dermatitis. Atopic dermatitis is a chronic, inflammatory skin condition with symptoms including areas of dry, itching and reddened skin. This study will also assess the safety and effectiveness of different doses of tezepelumab.
Tezepelumab is an experimental treatment which means that it is not an approved treatment for moderate to severe atopic dermatitis in Australia. Medications, drugs and devices have to be approved for use by the Therapeutic Goods Administration in Australia.
The purpose of this study is to compare the safety and effectiveness of PRN1008 as a treatment for pemphigus vulgaris (PV) and pemphigus foliaceus (PF) when taken with a corticosteroid and compare this to the safety and effectiveness of corticosteroid alone.
PRN1008 is an investigational drug developed by the study sponsor, Principia for the treatment of autoimmune and inflammatory diseases, such as pemphigus. PRN1008 is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor. BTK is an enzyme that plays a crucial role in B-cell development, a type of white blood cell that is involved in the immune system, and in the white blood cells’ role in diseases like PV or PF.
We are looking for people with Crohn's Disease to participate in a study to determine the safety and effictiveness of a new study medication, guselkumab.
Guselkumab is made in the laboratory and is a fully human monoclonal antibody. An antibody is something that targets and kills foreign objects in the body - in this case, small proteins that are released by cells and affect the behaviour of other cells. This antibody, guselkumab, recognizes and blocks a specific small protein, IL-23, which is important in immune and inflammatory processes.
The purpose of this research study is to compare the effects of the study drug, PF-06687234, with a placebo while also being treated with infliximab to find out which is better for treating Ulcerative Colitis (UC).
The study drug, PF-06687234 has two proteins that are connected to each other. One protein seeks out and attaches to areas of inflammation (for example the colon in UC). The second protein works to “calm down” the immune system in inflamed areas such as the colon, in UC. A placebo looks like the study drug but does not contain any active drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.
PF-06687234 is an experimental drug which means that it is not an approved treatment for UC in Australia.